bone resorption

Summary

Summary: Bone loss due to osteoclastic activity.

Top Publications

  1. ncbi Osteoclast differentiation and activation
    William J Boyle
    Protein Pathways, Inc, Woodland Hills, California 91367, USA
    Nature 423:337-42. 2003
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
  3. ncbi Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
    W S Simonet
    Department of Molecular Genetics, Amgen Inc, Thousand Oaks, California 91320, USA
    Cell 89:309-19. 1997
  4. pmc RANK is essential for osteoclast and lymph node development
    W C Dougall
    Immunex Corporation, Seattle, Washington 98101 USA
    Genes Dev 13:2412-24. 1999
  5. ncbi The molecular understanding of osteoclast differentiation
    Masataka Asagiri
    Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1 5 45, Tokyo 113 8549, Japan
    Bone 40:251-64. 2007
  6. ncbi Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
    Hiroshi Takayanagi
    Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1 5 45, Bunkyo ku, Tokyo 113 8549, Japan
    Nat Rev Immunol 7:292-304. 2007
  7. pmc Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
    Christopher T Ritchlin
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Clin Invest 111:821-31. 2003
  8. ncbi RANKL-RANK signaling in osteoclastogenesis and bone disease
    Teiji Wada
    Institute of Molecular Biotechnology of the Austrian Academy of Sciences IMBA, Dr Bohrgasse 3, A 1030 Vienna, Austria
    Trends Mol Med 12:17-25. 2006
  9. ncbi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    Y Y Kong
    Amgen Institute, Toronto, Ontario, Canada
    Nature 402:304-9. 1999
  10. ncbi Podosome and sealing zone: specificity of the osteoclast model
    Pierre Jurdic
    Laboratoire de Biologie Moléculaire et Cellulaire UMR 5161 CNRS ENS, IFR 128 BioSciences, Ecole Normale Superieure de Lyon, 46 allee d Italie, F 69007 Lyon, France
    Eur J Cell Biol 85:195-202. 2006

Research Grants

  1. Biomaterials (Mf/Zn/F-BCPs) for osteoporosis therapy
    RACQUEL ZAPANTA LEGEROS; Fiscal Year: 2010
  2. Biomaterials (Mf/Zn/F-BCPs) for osteoporosis therapy
    Racquel LeGeros; Fiscal Year: 2009
  3. BONE MATRIX AND BONE RESORPTION
    Paul R Odgren; Fiscal Year: 2010
  4. DEGRADABLE HYDROGELS FOR ORAL DELIVERY OF CALCITONIN
    Jindrich Kopecek; Fiscal Year: 2003
  5. PDGF D AND PROSTATE CANCER BONE METASTASIS
    Hyeong Reh Choi Kim; Fiscal Year: 2010
  6. Immune Cytokines Promote Oral Bone Loss Through IKK
    Cun Yu Wang; Fiscal Year: 2010
  7. Innate Immune Bacterial Recognition and Osteoclastogenesis
    Caroline A Genco; Fiscal Year: 2010
  8. Molecular Mechanisms in Bone Resorption
    STEVEN LIETMAN; Fiscal Year: 2009
  9. Molecular Mechanisms in Bone Resorption
    Steven A Lietman; Fiscal Year: 2010
  10. The Effect of PTHrP During Lactation
    John Wysolmerski; Fiscal Year: 2007

Detail Information

Publications329 found, 100 shown here

  1. ncbi Osteoclast differentiation and activation
    William J Boyle
    Protein Pathways, Inc, Woodland Hills, California 91367, USA
    Nature 423:337-42. 2003
    ..pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass...
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
    ..These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development...
  3. ncbi Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
    W S Simonet
    Department of Molecular Genetics, Amgen Inc, Thousand Oaks, California 91320, USA
    Cell 89:309-19. 1997
    A novel secreted glycoprotein that regulates bone resorption has been identified. The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily...
  4. pmc RANK is essential for osteoclast and lymph node development
    W C Dougall
    Immunex Corporation, Seattle, Washington 98101 USA
    Genes Dev 13:2412-24. 1999
    ..These experiments reveal that RANK provides critical signals necessary for lymph node organogenesis and osteoclast differentiation...
  5. ncbi The molecular understanding of osteoclast differentiation
    Masataka Asagiri
    Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1 5 45, Tokyo 113 8549, Japan
    Bone 40:251-64. 2007
    ..From the clinical point of view, RANKL signaling pathway has promise as a strategy for suppressing the excessive osteoclast formation characteristic of a variety of bone diseases...
  6. ncbi Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
    Hiroshi Takayanagi
    Department of Cell Signaling, Graduate School, Tokyo Medical and Dental University, Yushima 1 5 45, Bunkyo ku, Tokyo 113 8549, Japan
    Nat Rev Immunol 7:292-304. 2007
    ....
  7. pmc Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
    Christopher T Ritchlin
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Clin Invest 111:821-31. 2003
    Psoriatic arthritis (PsA) is an inflammatory joint disease characterized by extensive bone resorption. The mechanisms underlying this matrix loss have not been elucidated...
  8. ncbi RANKL-RANK signaling in osteoclastogenesis and bone disease
    Teiji Wada
    Institute of Molecular Biotechnology of the Austrian Academy of Sciences IMBA, Dr Bohrgasse 3, A 1030 Vienna, Austria
    Trends Mol Med 12:17-25. 2006
    ....
  9. ncbi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    Y Y Kong
    Amgen Institute, Toronto, Ontario, Canada
    Nature 402:304-9. 1999
    ..These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology...
  10. ncbi Podosome and sealing zone: specificity of the osteoclast model
    Pierre Jurdic
    Laboratoire de Biologie Moléculaire et Cellulaire UMR 5161 CNRS ENS, IFR 128 BioSciences, Ecole Normale Superieure de Lyon, 46 allee d Italie, F 69007 Lyon, France
    Eur J Cell Biol 85:195-202. 2006
    The bone resorption function of osteoclasts is dependent on the integrity of the actin cytoskeleton...
  11. ncbi Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis
    Takako Koga
    Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nature 428:758-63. 2004
    ..These results reveal that RANKL and M-CSF are not sufficient to activate the signals required for osteoclastogenesis...
  12. ncbi IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology
    Steeve Kwan Tat
    Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, BP 53508, 44035 Nantes 1, France
    Cytokine Growth Factor Rev 15:49-60. 2004
    ..The interactions between these three groups are presented within the framework of bone resorption pathophysiology such as tumor associated osteolysis...
  13. ncbi Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption
    Alice Wattel
    Clinical Pharmacy Laboratory, Universite de Picardie Jules Verne, 1 rue des Louvels, 80000 Amiens, France
    Biochem Pharmacol 65:35-42. 2003
    ..Our results indicate that both compounds, at concentrations ranging from 0.1 to 100 microM reduce bone resorption in a time and dose-dependent manner...
  14. pmc Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention
    Sougata Karmakar
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, UMass Memorial Medical Center, Lazare Research Building, Suite 223, 364 Plantation Street, Worcester, MA 01605, USA
    Rheum Dis Clin North Am 36:385-404. 2010
    ..In this review, the authors discuss the current understanding of pathogenic mechanisms of bone erosion in RA and examine current therapeutic approaches to prevent this damage...
  15. ncbi Leptin regulation of bone resorption by the sympathetic nervous system and CART
    Florent Elefteriou
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA
    Nature 434:514-20. 2005
    ..Here we show, by analysing Adrb2-deficient mice, that the sympathetic nervous system favours bone resorption by increasing expression in osteoblast progenitor cells of the osteoclast differentiation factor Rankl...
  16. pmc Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption
    Sarah Schmidt
    Max Planck Institute of Biochemistry, D 82152 Martinsried, Germany
    J Cell Biol 192:883-97. 2011
    ..expressed on osteoclasts, which in turn abrogates the formation of podosomes and sealing zones required for bone resorption. In agreement with these findings, genetic ablation of all integrin classes abolishes the development of ..
  17. doi Experimental results of combining bisphosphonates with allograft in a rat model
    F Agholme
    Department of Clinical and Experimental Medicine, Section for Orthopaedics and Sports Medicine, Linkoping University, Linkoping, Sweden
    J Bone Joint Surg Br 91:670-5. 2009
    ..We suggest that bisphosphonates are likely to have a negative influence where resorption is a prerequisite to create space for new bone ingrowth...
  18. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007
    ..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth.
  19. ncbi Expression of bone resorption genes in osteoarthritis and in osteoporosis
    Darja Bitenc Logar
    Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Askerceva 7, SI 1000, Ljubljana, Slovenia
    J Bone Miner Metab 25:219-25. 2007
    ..TRAP is a marker for osteoclasts, and there is increasing evidence of its proteolytic role in bone resorption. RANKL is a recently discovered regulator of osteoclast maturation and activity and induces expression of ..
  20. ncbi TSH is a negative regulator of skeletal remodeling
    Etsuko Abe
    Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell 115:151-62. 2003
    ..effects of TSH on both components of skeletal remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH receptor (TSHR) found on osteoblast and osteoclast precursors...
  21. pmc Cellular and molecular mechanisms of bone remodeling
    Liza J Raggatt
    Faculty of Health Sciences, The University of Queensland Centre for Clinical Research, Royal Brisbane Hospital, Herston 4029, Australia
    J Biol Chem 285:25103-8. 2010
    Physiological bone remodeling is a highly coordinated process responsible for bone resorption and formation and is necessary to repair damaged bone and to maintain mineral homeostasis...
  22. pmc A crucial role for thiol antioxidants in estrogen-deficiency bone loss
    Jenny M Lean
    Department of Cellular Pathology, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom
    J Clin Invest 112:915-23. 2003
    ..This directly sensitizes osteoclasts to osteoclastogenic signals and entrains ROS-enhanced expression of cytokines that promote osteoclastic bone resorption.
  23. pmc Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength
    M Chellaiah
    Renal Division, Department of Medicine, Barnes Jewish Hospital, Washington University, St Louis, Missouri 63110, USA
    J Cell Biol 148:665-78. 2000
    ..binding to the alpha(v)beta(3) integrin of osteoclast podosomes stimulated cytoskeletal reorganization and bone resorption by activating a heteromultimeric signaling complex that includes gelsolin, pp(60c-src), and ..
  24. pmc The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
    T L Burgess
    Department of Mammalian Cell Molecular Biology, Amgen Inc, Thousand Oaks, California 91320 1789, USA
    J Cell Biol 145:527-38. 1999
    ..within 30 min) induces actin ring formation; a marked cytoskeletal rearrangement that necessarily precedes bone resorption. Furthermore, we show that antibodies raised against the OPGL receptor, RANK, also induce actin ring ..
  25. doi Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL
    Paul J Kostenuik
    Metabolic Disorders Research, Amgen, Thousand Oaks, California 91320, USA
    J Bone Miner Res 24:182-95. 2009
    ..Recombinant human OPG-Fc recognizes RANKL from multiple species and reduced bone resorption and increased bone volume, density, and strength in a number of rodent models of bone disease...
  26. pmc Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
    Guitty Eghbali-Fatourechi
    Endocrine Research Unit, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Invest 111:1221-30. 2003
    ..Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all ..
  27. doi Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis
    Tsai Pei Hsieh
    School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan, ROC
    Phytomedicine 18:176-85. 2011
    ..Our hypothesis is that icariin can inhibit osteoclast differentiation and bone resorption by suppressing MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis...
  28. doi Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women
    E S Mackinnon
    Department of Medicine, Division of Endocrinology and Metabolism, St Michael s Hospital, 30 Bond St, Toronto, ON, Canada M5B 1W8
    Osteoporos Int 22:1091-101. 2011
    ..with lycopene had significantly increased antioxidant capacity and decreased oxidative stress and the bone resorption marker N-telopeptide (NTx). Lycopene decreases bone resorption markers and may reduce the risk of osteoporosis...
  29. ncbi Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation
    Jenny M Lean
    Department of Cellular Pathology, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom
    Endocrinology 146:728-35. 2005
    ..We found that catalase prevented ovariectomy-induced bone loss. These results suggest that hydrogen peroxide is the reactive oxygen species responsible for signaling the bone loss of estrogen deficiency...
  30. doi S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis
    Lilyanne C Grevers
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Arthritis Rheum 63:1365-75. 2011
    ..The aim of the present study was to investigate the role of S100A8 and S100A9 in osteoclastic bone destruction in murine antigen-induced arthritis (AIA)...
  31. pmc Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
    R Kitazawa
    Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, Missouri
    J Clin Invest 94:2397-406. 1994
    ..Ovx also increased bone resorption in vivo and in vitro, as assessed by the urinary excretion of pyridinoline cross links and the formation of ..
  32. ncbi Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
    Paul J Kostenuik
    Metabolic Disorders Research, M S 15 2 B, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Curr Opin Pharmacol 5:618-25. 2005
    ..Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG...
  33. ncbi Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation
    Jung Min Koh
    Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Songpa Gu, Seoul, Korea
    J Bone Miner Res 21:1003-11. 2006
    ..Physiologic concentrations of Hcy directly activate osteoclast formation and activity through stimulation of p38 MAPK and integrin beta3. The effects of Hcy were mediated by generation of intracellular ROS...
  34. ncbi NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells
    Shuting Bai
    Departments of Pathology and Immunology, Molecular Biology and Pharmacology, and Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Biol Chem 283:6509-18. 2008
    ..We find that attenuated NOTCH signaling enhances osteoclastogenesis and bone resorption in vitro and in vivo by a combination of molecular mechanisms...
  35. pmc Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction
    Kojiro Sato
    Department of Cell Signaling, Graduate School, and COE Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Tokyo Medical and Dental University, Tokyo 113 8549, Japan
    J Exp Med 203:2673-82. 2006
    ..a specialized inflammatory subset, as an osteoclastogenic Th cell subset that links T cell activation and bone resorption. The interleukin (IL)-23-IL-17 axis, rather than the IL-12-IFN-gamma axis, is critical not only for the onset ..
  36. pmc RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro
    Shuying Yang
    Department of Cytokine Biology, The Forsyth Institute, Boston, MA 02115, USA
    J Bone Miner Res 22:45-54. 2007
    ..RGS12 may play a critical role in the RANKL-evoked PLCgamma-calcium channels-[Ca(2+)](i) oscillation-NFAT2 pathway...
  37. pmc Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice
    Wei Jin
    Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1858-66. 2008
    ..These findings establish CYLD as a crucial negative regulator of osteoclastogenesis and suggest its involvement in the p62/TRAF6 signaling axis...
  38. doi NFATc1: functions in osteoclasts
    Qingxiao Zhao
    College of Chemical Engineering, Northeast Dianli University, Changchun Road 169, Jilin, PR China
    Int J Biochem Cell Biol 42:576-9. 2010
    ..In the present review, some of the known features of NFATc1 such as structure, function and its roles in physiological or pathophysiological processes are highlighted...
  39. doi Rheumatoid arthritis and periodontal disease
    Jean Marie Berthelot
    Service de Rhumatologie, Hotel Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Joint Bone Spine 77:537-41. 2010
    ..g., scaling, root planing and, if needed, dental surgery), particularly as periodontitis is also associated with an increased risk of premature atheroma...
  40. doi IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss
    Mario M Zaiss
    Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen Nuremberg, D 91054 Erlangen, Germany
    J Immunol 186:6097-105. 2011
    ..Thus, we show in this study that IL-33 is an important bone-protecting cytokine and may be of therapeutic benefit in treating bone resorption.
  41. pmc Osteoclasts have multiple roles in bone in addition to bone resorption
    Brendan F Boyce
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Crit Rev Eukaryot Gene Expr 19:171-80. 2009
    ..Recent studies have identified functions for OCPs and osteoclasts in and around bone other than bone resorption. For example, they regulate the differentiation of osteoblast precursors and the movement of hematopoietic ..
  42. pmc Functions of RANKL/RANK/OPG in bone modeling and remodeling
    Brendan F Boyce
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Arch Biochem Biophys 473:139-46. 2008
    The discovery of the RANKL/RANK/OPG system in the mid 1990s for the regulation of bone resorption has led to major advances in our understanding of how bone modeling and remodeling are regulated...
  43. ncbi Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases
    K Henriksen
    Nordic Bioscience A S, Herlev, Denmark
    Osteoporos Int 18:681-5. 2007
    Numerous experimental and clinical observations suggest that overall changes in bone resorption during menopause or treatment with hormone replacement therapy (HRT) are combined effects of changes in osteoclast number and function...
  44. doi Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation
    Estabelle S M Ang
    School of Dentistry, Oral Biology Research Laboratory, The University of Western Australia, Nedlands, WA 6009, Australia
    FEBS Lett 585:2755-62. 2011
    ..Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteoclast formation and bone resorption. Naringin, a natural occurring flavonoid has been found to protect against retinoic acid-induced osteoporosis ..
  45. pmc Osteoclast motility: putting the brakes on bone resorption
    Deborah V Novack
    Department of Medicine, St Louis, MO 63110, USA
    Ageing Res Rev 10:54-61. 2011
    ..The osteoclast is the specialized cell that is responsible for bone resorption. It is a highly polarized cell that must adhere to the bone surface and migrate along it while resorbing, and ..
  46. doi Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro
    Leilei Bao
    Department of Pharmacogonosy, School of Pharmacy, Second Military Medical University, Shanghai, China
    Chem Biol Interact 194:97-105. 2011
    ..1, 3, 8-trihydroxy-2-methoxy-anthraquinone (1), 2-hydroxy-1-methoxy-anthraquinone (2) and rubiadin (3) on bone resorption activity in vitro and the mechanism on osteoclasts derived from rat bone marrow cells...
  47. pmc An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption
    B S Herrera
    Department of Periodontology and Oral Biology, Goldman School of Dental Medicine, Boston University, Boston, MA 2118, USA
    Br J Pharmacol 155:1214-23. 2008
    ..It was of interest to determine whether RvE1 has direct actions on osteoclast (OC) development and bone resorption.
  48. doi Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
    Sarah J Glover
    University of Sheffield, Sheffield, UK
    Bone 45:1053-8. 2009
    ..increases in biochemical markers of bone formation after 1 month of therapy followed by a delayed increase in bone resorption markers...
  49. pmc Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency
    M Neale Weitzmann
    Division of Bone and Mineral Diseases, Washington University School of Medicine and Barnes Jewish Hospital, St Louis, Missouri, USA
    J Clin Invest 110:1643-50. 2002
    ..bone loss stems from the inability of osteoblastic activity to match the increase in osteoclastic bone resorption induced by estrogen deficiency...
  50. pmc Control of bone resorption by semaphorin 4D is dependent on ovarian function
    Romain Dacquin
    Institut de Génomique Fonctionnelle de Lyon, Universite de Lyon, CNRS, Ecole Normale Superieure de Lyon, Lyon, France
    PLoS ONE 6:e26627. 2011
    ..It is well established that bone mass, which results from a balanced bone formation and bone resorption, is regulated by many hormonal, environmental and genetic factors...
  51. doi The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis
    Tomoyuki Nakasa
    Department of Orthopaedic Surgery, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
    Arthritis Rheum 63:1582-90. 2011
    ..This study was undertaken to examine whether miR-146a expression inhibits osteoclastogenesis, and whether administration of miR-146a prevents joint destruction in mice with collagen-induced arthritis (CIA)...
  52. ncbi Therapeutic approaches to bone diseases
    G A Rodan
    Merck Research Laboratories, West Point, PA 19486, USA St Vincent s Institute of Medical Research, Melbourne 3065, Australia
    Science 289:1508-14. 2000
    The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts...
  53. ncbi The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro
    S Greiner
    Center for Musculoskeletal Surgery, Charite Universitatsmedizin Berlin, Germany
    J Biomed Mater Res A 80:769-75. 2007
    ..Changes in sRANKL and OPG production may contribute to the inhibition of osteoclastic bone resorption. This local antiresorptive effect might be clinically useful in osseous implant integration and fracture ..
  54. ncbi Cell biology of the osteoclast
    G D Roodman
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Exp Hematol 27:1229-41. 1999
    ..The identification of the role of oncogenes such as c-fos and pp60 c-src in osteoclast differentiation and bone resorption have provided important insights in the regulation of normal osteoclast activity...
  55. ncbi Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy
    Wende Kozlow
    Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, 22908, USA
    J Mammary Gland Biol Neoplasia 10:169-80. 2005
    ..These factors and their roles in fueling the vicious cycle may identify novel targets for therapies to prevent metastasis...
  56. ncbi Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...
  57. ncbi Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection
    Robert E Miller
    Department of Cancer Biology, Amgen Washington, 1201 Amgen Court West, Seattle, WA 98119, USA
    J Immunol 179:266-74. 2007
    ..RANK-Fc inhibition of RANKL has antiosteoclast activity at doses that have no detectable immunoregulatory activity, suggesting that RANKL inhibitors be further studied for their potential to treat excess bone loss...
  58. doi Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro
    C Y Luo
    Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, China
    Cell Mol Immunol 8:50-8. 2011
    ..we investigated the impact of CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cells on osteoclastogenesis and bone resorption. Treg cells that were isolated and purified from peripheral blood mononuclear cells (PBMCs) of healthy adults ..
  59. ncbi The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function
    William C Horne
    Department of Orthopaedics and Rehabilitation and Cell Biology, Yale University School of Medicine, New Haven, CT 06520 8044, USA
    Immunol Rev 208:106-25. 2005
    ..secretory domain (the ruffled border) and attachment-related cytoskeletal elements that are necessary for bone resorption. A key function of Src in osteoclasts is to promote the rapid assembly and disassembly of the podosomes, the ..
  60. doi Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofa
    Toshiyuki Yoneda
    Department of Biochemistry, Osaka University Graduate School of Dentistry, 1 8 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Bone Miner Metab 28:365-83. 2010
    ....
  61. ncbi Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression
    A M Parfitt
    Division of Endocrinology and Center for Osteoporosis and Metabolic Bone Disease, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Bone 30:5-7. 2002
  62. doi Impact of intra- and extra-osseous soft tissue composition on changes in bone mineral density with weight loss and regain
    Anja Bosy-Westphal
    the Institute of Human Nutrition and Food Science, Christian Albrechts University, Kiel, Germany
    Obesity (Silver Spring) 19:1503-10. 2011
    ..In conclusion, changes in extra-osseous soft tissue composition had a minor contribution to changes in BMD with weight loss and decreases in bone marrow adipose tissue (BMAT) were not related to changes in BMD...
  63. pmc Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice
    Firas M Kara
    New York University School of Medicine, New York, NY, USA
    Arthritis Rheum 62:534-41. 2010
    Accelerated osteoclastic bone resorption plays a central role in the pathogenesis of osteoporosis and other bone diseases...
  64. pmc Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction
    Norbert Kartner
    Dental Research Institute, Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1G6 Canada
    J Biol Chem 285:37476-90. 2010
    ..Further understanding of these interactions and inhibitors may contribute to the design of novel therapeutics for bone loss disorders, such as osteoporosis and rheumatoid arthritis...
  65. pmc Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts
    K P McHugh
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Clin Invest 105:433-40. 2000
    Osteoclasts express the alphavbeta3 integrin, an adhesion receptor that has been implicated in bone resorption and that is therefore a potential therapeutic target...
  66. doi Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity
    Estabelle S M Ang
    Molecular Orthopaedic Laboratory, Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Nedlands, Western Australia, Australia
    J Cell Physiol 221:642-9. 2009
    ..In this study, we investigated the effect of CAPE on the regulation of RANKL-induced osteoclastogenesis, bone resorption and signaling pathways...
  67. doi Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model
    XiaoYan Tian
    Radiobiology Division, University of Utah School of Medicine, Salt Lake City, UT, USA
    Bone 48:197-201. 2011
    ..in a rat immobilization/disuse model in which there was both a decrease in bone formation and an increase in bone resorption. Ten-month-old female Sprague Dawley rats were divided into normal weight-bearing (normal-loaded, NL) and ..
  68. ncbi Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases
    Lorenz C Hofbauer
    Department of Gastroenterology, Philipps University, Marburg, Germany
    JAMA 292:490-5. 2004
    b>Bone resorption by osteoclasts is coupled with bone formation by osteoblasts, and this balanced process continuously remodels and adapts the skeleton...
  69. doi Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption
    Arpita Chakravarti
    Centre de Recherche en Rhumatologie et Immunologie CRRI, CRCHUL and Department of Medicine, Faculty of Medicine, Universite Laval, Quebec, QC, Canada
    Blood 114:1633-44. 2009
    ..7 cells, respectively, stimulated bone resorption. Transfection of PLB-985 neutrophil-like cells with RANKL antisense RNA reduced osteoclastogenesis...
  70. ncbi In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis
    Lisa M Childs
    Department of Microbiology and Immunology, University of Rochester Medical Center, New York 14642, USA
    J Bone Miner Res 17:192-9. 2002
    ..process and the requirements of receptor activator of NF-kappaB (RANK) signaling in osteoclastogenesis and bone resorption, we investigated the efficacy of RANK blockade in preventing and ameliorating titanium (Ti)-induced ..
  71. ncbi Src kinase activity is essential for osteoclast function
    Tsuyoshi Miyazaki
    Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Biol Chem 279:17660-6. 2004
    ..Eliminating the Src-binding site on Pyk2 (Pyk2(Y402F)) markedly inhibited bone resorption by osteoclast-like cells, whereas kinase-dead Pyk2 had little effect...
  72. doi Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis
    Marc Baud'huin
    INSERM, UMR S 957, Nantes F 44035, France
    J Pathol 221:77-86. 2010
    ..Overall, these data reveal that IL-34 can be entirely substituted for M-CSF in RANKL-induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs...
  73. pmc DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells
    Mitsuru Yagi
    Department of Cell Differentiation, The Sakaguchi Laboratory, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    J Exp Med 202:345-51. 2005
    ..We have thus identified an essential regulator of osteoclast and macrophage cell fusion, DC-STAMP, and an essential role of osteoclast multinucleation in bone homeostasis...
  74. pmc I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss
    Maria Grazia Ruocco
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    J Exp Med 201:1677-87. 2005
    ..IKKbeta also protects osteoclasts and their progenitors from tumor necrosis factor alpha-induced apoptosis, and its loss in hematopoietic cells prevents inflammation-induced bone loss...
  75. ncbi MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
    K Holmbeck
    MMP Unit, National Institute of Dental and Craniofacial Research, Bethesda, Maryland 20892, USA
    Cell 99:81-92. 1999
    ....
  76. ncbi Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption
    J E Aubin
    Department of Anatomy and Cell Biology, Faculty of Medicine, University of Toronto, Ontario, Canada
    Osteoporos Int 11:905-13. 2000
    ..paradigm for both differentiation of osteoclasts and their activation has had tremendous impact on the field and opened new avenues for development of possible treatments of diseases characterized by excessive bone resorption.
  77. doi Regulatory T cells protect from local and systemic bone destruction in arthritis
    Mario M Zaiss
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 184:7238-46. 2010
    ..In this article, we show that blood markers of bone resorption inversely correlate with the amount of circulating Treg cells in healthy controls and rheumatoid arthritis ..
  78. pmc Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions
    Feng Chun Yang
    Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Clin Invest 116:2880-91. 2006
    ..Collectively, our results identify a what we believe to be a novel cellular and biochemical NF1-haploinsufficient phenotype in osteoclasts that has potential implications for the pathogenesis of NF1 bone disease...
  79. doi Osteoclast culture and resorption assays
    Elizabeth W Bradley
    Mayo Clinic Graduate School, Rochester, MN, USA
    Methods Mol Biol 455:19-35. 2008
    Bone homeostasis depends on balanced bone deposition and bone resorption, which are mediated by osteoblasts and osteoclasts, respectively. The process of bone turnover requires the coordination of these cells...
  80. doi Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation
    Mario M Zaiss
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:2328-38. 2010
    ..The aim of this study was to determine whether immune regulatory mechanisms, such as naturally occurring Treg cells, also extend their protective effects to bone homeostasis in vivo...
  81. ncbi Multiple roles of M-CSF in human osteoclastogenesis
    Jason M Hodge
    The Department of Clinical and Biomedical Sciences Barwon Health, The University of Melbourne, Geelong, Victoria 3220, Australia
    J Cell Biochem 102:759-68. 2007
    ..Modulation of M-CSF signaling is a potential therapeutic target for conditions associated with excess bone resorption.
  82. pmc Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes
    Se Hwan Mun
    Institute of Biomedical Sciences and Technology, Konkuk University, Chungju, Korea
    Cell Mol Life Sci 67:3883-92. 2010
    ..IL-33 eventually induced bone resorption. This study suggests that the osteoclastogenic property of IL-33 is mediated through TRAF6 as well as the ..
  83. ncbi Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation
    Hong Hee Kim
    National Research Laboratory for Bone Metabolism, Department of Microbiology and Immunology, College of Medicine, Chosun University, Gwangju 501 759, Korea
    Exp Cell Res 289:368-77. 2003
    ....
  84. doi Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL
    Lorenz C Hofbauer
    Department of Medicine III, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Arthritis Rheum 60:1427-37. 2009
    ..This study was undertaken to evaluate the efficacy of denosumab, a neutralizing monoclonal antibody against human RANKL (hRANKL), in a murine model of glucocorticoid-induced osteoporosis...
  85. doi The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss
    Christina Böhm
    Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 183:5938-47. 2009
    ..Thus, our data show that developing specific inhibitors of the alpha-isoenzyme of p38 would be beneficial for the treatment of inflammation-induced bone destruction as observed in rheumatoid arthritis...
  86. doi Clinical applications of RANK-ligand inhibition
    E Romas
    Rheumatology Research Unit, St Vincent s Institute, University of Melbourne, Melbourne, Victoria, Australia
    Intern Med J 39:110-6. 2009
    ..g. denosumab) and which induce profound and sustained inhibition of bone resorption. The relative efficacy, cost-effectiveness and side-effects of targeted RANKL inhibition compared with ..
  87. pmc Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women
    Matthew T Drake
    Division of Endocrinology and Metabolism, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 95:5063-8. 2010
    It has recently been proposed that the increase in bone resorption after the menopause may not be due principally to estrogen deficiency but rather to the concomitant increase in circulating FSH levels.
  88. ncbi Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio
    Riku Kiviranta
    Department of Medical Biochemistry and Molecular Biology, University of Turku, Kiinamyllynkatu 10, FIN 20520 Turku, Finland
    Bone 36:159-72. 2005
    Previous reports indicate that mice deficient for cathepsin K (Ctsk), a key protease in osteoclastic bone resorption, develop osteopetrosis due to their inability to properly degrade organic bone matrix...
  89. ncbi Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
    B D Gelb
    Department of Human Genetics and Division of Pediatric Cardiology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Science 273:1236-8. 1996
    ..These findings suggest that cathepsin K is a major protease in bone resorption, providing a possible rationale for the treatment of disorders such as osteoporosis and certain forms of ..
  90. doi Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis
    Pauline M Camacho
    Division of Endocrinology and Metabolism, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA
    Clin Chem Lab Med 46:1345-57. 2008
    ..The aim of this review is to present data which helps elucidate the current role and limitation of BTMs in the management of osteoporosis...
  91. pmc Tctex-1, a novel interaction partner of Rab3D, is required for osteoclastic bone resorption
    Nathan J Pavlos
    Centre for Orthopaedic Research, School of Surgery, University of Western Australia, Perth 6009, Western Australia, Australia
    Mol Cell Biol 31:1551-64. 2011
    ..Finally, targeted disruption of Tctex-1 by RNA interference significantly impairs bone resorption capacity and mislocalizes Rab3D vesicles in osteoclasts, attesting to the notion that components of the Rab3D-..
  92. doi Bone turnover markers in the management of postmenopausal osteoporosis
    Jacques P Brown
    Universite Laval, Quebec, QC, Canada
    Clin Biochem 42:929-42. 2009
    ..However, when remodelling becomes accelerated in combination with an imbalance that favours bone resorption over formation, such as during menopause, precipitous losses in bone mass occur...
  93. pmc Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease
    C W O Ernst
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    Clin Exp Immunol 148:271-80. 2007
    Periodontal disease involves multi-bacterial infections accompanied by inflammatory bone resorption lesions...
  94. ncbi Bone formation versus bone resorption in ankylosing spondylitis
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Adv Exp Med Biol 649:114-21. 2009
    ..AS may thus be considered as a synthesis of inflammatory disease and bone disease...
  95. pmc Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption
    Nathan J Pavlos
    Unit of Orthopaedics, School of Surgery and Pathology, University of Western Australia, 2nd Floor M Block, QEII Medical Centre, Nedlands, Perth, Western Australia 6009, Australia
    Mol Cell Biol 25:5253-69. 2005
    ..prenylation-deficient Rab3D has no significant effects, overexpression of GTP-binding-deficient Rab3D impairs bone resorption in vitro...
  96. doi Postgraduate Symposium: Positive influence of nutritional alkalinity on bone health
    E Wynn
    University Hospital CHUV, 1011 Lausanne, Switzerland
    Proc Nutr Soc 69:166-73. 2010
    ..been shown in a group of thirty young women that in Ca sufficiency an acid Ca-rich water has no effect on bone resorption, while an alkaline bicarbonate-rich water leads to a decrease in both serum parathyroid hormone and serum C-..
  97. pmc The p85alpha subunit of class IA phosphatidylinositol 3-kinase regulates the expression of multiple genes involved in osteoclast maturation and migration
    Veerendra Munugalavadla
    Department of Pediatrics, Herman B Wells Center for Pediatric Research, 2 Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Mol Cell Biol 28:7182-98. 2008
    ..to adhere to as well as to migrate via integrin alphavbeta3 was observed, which was associated with reduced bone resorption. Microarray as well as quantitative real-time PCR analysis of p85alpha(-/-) osteoclasts revealed a ..
  98. pmc Osteoclasts are active in bone forming metastases of prostate cancer patients
    Ilaria Roato
    CeRMS Center for Experimental Research and Medical Studies University and A O U San Giovanni Battista, Turin, Italy
    PLoS ONE 3:e3627. 2008
    ..In this study, we investigated ex vivo whether the osteolytic activity is present and how it is ruled in CaP patients with bone forming metastases...
  99. ncbi Onion and a mixture of vegetables, salads, and herbs affect bone resorption in the rat by a mechanism independent of their base excess
    Roman C Muhlbauer
    Department Clinical Research, University of Bern, Switzerland
    J Bone Miner Res 17:1230-6. 2002
    ..We showed previously that in the rat the consumption of several vegetables, salads, and herbs inhibits bone resorption and that onion increases bone mass...
  100. ncbi Intake of fruit and vegetables: implications for bone health
    Susan A New
    Centre for Nutrition and Food Safety, School of Biomedical and Molecular Sciences, University of Surrey, Guildford GU2 7XH, Surrey, UK
    Proc Nutr Soc 62:889-99. 2003
    ....
  101. ncbi Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis
    Andrea Dovio
    Medicina Interna I, Dipartimento di Scienze Cliniche e Biologiche, University of Turin, 10043 Orbassano, Italy
    J Clin Endocrinol Metab 89:4923-8. 2004
    ..regimens cause an immediate and persistent decrease in bone formation and a rapid and transient increase of bone resorption. Our data also support the concept that discontinuation of such regimens is followed by a high bone turnover ..

Research Grants82

  1. Biomaterials (Mf/Zn/F-BCPs) for osteoporosis therapy
    RACQUEL ZAPANTA LEGEROS; Fiscal Year: 2010
    Osteoporosis, a silent debilitating bone disease, results when the rate of bone resorption (by osteoclasts) is much greater than the rate of bone formation (by osteoblasts) causing bone loss, deterioration of bone quality, leading to ..
  2. Biomaterials (Mf/Zn/F-BCPs) for osteoporosis therapy
    Racquel LeGeros; Fiscal Year: 2009
    Osteoporosis, a silent debilitating bone disease, results when the rate of bone resorption (by osteoclasts) is much greater than the rate of bone formation (by osteoblasts) causing bone loss, deterioration of bone quality, leading to ..
  3. BONE MATRIX AND BONE RESORPTION
    Paul R Odgren; Fiscal Year: 2010
    ..translocate OC secretory vesicles to the RB and secrete their contents into the resorption lacuna to effect bone resorption. Under SA1...
  4. DEGRADABLE HYDROGELS FOR ORAL DELIVERY OF CALCITONIN
    Jindrich Kopecek; Fiscal Year: 2003
    ..The rationales for hCT use in osteoporosis therapy are the stimulation of osteoblasts, specific inhibition of bone resorption by osteoclasts, and prevention of fusion of osteoclast precursors...
  5. PDGF D AND PROSTATE CANCER BONE METASTASIS
    Hyeong Reh Choi Kim; Fiscal Year: 2010
    ..mechanisms by which prostate carcinoma-produced platelet-derived growth factor (PDGF) regulates osteoclastic bone resorption and new bone growth, creating a favorable microenvironment for metastatic deposit...
  6. Immune Cytokines Promote Oral Bone Loss Through IKK
    Cun Yu Wang; Fiscal Year: 2010
    ..Under physiological condition, bone resorption is delicately balanced and coupled with bone extracellular matrix deposition or bone formation, ensuring that ..
  7. Innate Immune Bacterial Recognition and Osteoclastogenesis
    Caroline A Genco; Fiscal Year: 2010
    ..In other inflammatory bone diseases these cells have been reported to contribute to the acceleration of bone resorption by the production of proinflammatory cytokines including tumor necrosis factor (TNF)-, interleukin (IL)-1, IL-..
  8. Molecular Mechanisms in Bone Resorption
    STEVEN LIETMAN; Fiscal Year: 2009
    ..of the etiology, osteoporosis is characterized by an imbalance in bone remodeling, such that osteoclastic bone resorption exceeds osteoblastic bone formation, which leads to low bone mass or osteopenia...
  9. Molecular Mechanisms in Bone Resorption
    Steven A Lietman; Fiscal Year: 2010
    ..of the etiology, osteoporosis is characterized by an imbalance in bone remodeling, such that osteoclastic bone resorption exceeds osteoblastic bone formation, which leads to low bone mass or osteopenia...
  10. The Effect of PTHrP During Lactation
    John Wysolmerski; Fiscal Year: 2007
    ..The resulting low estrogen levels, in turn, accelerate bone resorption and cause bone loss. In addition, the lactating breast secretes PTHrP into the systemic circulation and milk...
  11. The Effect of PTHrP During Lactation
    John J Wysolmerski; Fiscal Year: 2010
    ..The resulting low estrogen levels, in turn, accelerate bone resorption and cause bone loss. In addition, the lactating breast secretes PTHrP into the systemic circulation and milk...
  12. CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
    Philip Osdoby; Fiscal Year: 2002
    ..and activity and therefore influence normal and pathological osteoclastogenesis and osteoclast-mediated bone resorption. We have shown that osteoclasts produce small proinflammatory molecules known as chemokines, such as IL-8 and ..
  13. MVNP, p62P392L and IL-6 in the Pathogenesis of PD
    G Roodman; Fiscal Year: 2009
    ..both the p38 MAPK and PLC32/CREB pathways to increase IL-6 production, OCL numbers, nuclei per OCL and OCL bone resorption capacity...
  14. BONE TARGETED DELIVERY OF ANABOLIC AGENTS
    JINDRICH H KOPECEK; Fiscal Year: 2010
    ..Previous experiments have demonstrated that D-Asp8-targeted conjugates are preferentially incorporated onto bone resorption surfaces. This offers a unique opportunity to target drugs to sites of active bone resorption...
  15. BONE TARGETED DELIVERY OF ANABOLIC AGENTS
    Jindrich Kopecek; Fiscal Year: 2009
    ..Previous experiments have demonstrated that D-Asp8-targeted conjugates are preferentially incorporated onto bone resorption surfaces. This offers a unique opportunity to target drugs to sites of active bone resorption...
  16. MATRIX PROTEIN/INTEGRIN MEDIATED OSTEOCLAST REGULATION
    Keith Hruska; Fiscal Year: 1999
    ..progress has been made in the understanding of bone remodeling, especially related to the cell biology of bone resorption, in recent years...
  17. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2006
    These studies, all derived from our previous work exploring the interactions of bone matrix and bone resorption, focus on genes and other factors impacting skeletal development and resorption...
  18. ROLE FOR IL6 IN PTH INDUCED BONE RESORPTION
    Karl Insogna; Fiscal Year: 2001
    ..Of the various subtypes of this disease, postmenopausal osteoporosis is by far the most common. Increased bone resorption is the principal mechanism for bone loss in postmenopausal osteoporosis, and recent evidence indicates that ..
  19. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2009
    ..It is a competitive revision request for grant RO1 DE 007444, "Bone matrix and bone resorption," under which we are investigating the osteoclast cell biology of a protein we discovered called plekhm1...
  20. ENDOSTEAL BONE VOLUME REGULATION AND OSTEOPOROSIS
    Subburaman Mohan; Fiscal Year: 2010
    ..Instead, this reduction in trabecular bone volume in Cldn-18 knockout mice is caused by increased bone resorption as reflected by increased osteoclast (OC) number that is not compensated by a corresponding increase in ..
  21. The Mechanism of Coupling Bone Resorption and Formation
    Xu Cao; Fiscal Year: 2007
    ..The sequence is always the same - activation of osteoclast precursors and osteoclastic bone resorption, followed by osteoblastic bone formation to repair the defects...
  22. Effect of HIV Infection and HAART on Bone Homeostasis
    MERVYN NEALE contact WEITZMANN; Fiscal Year: 2010
    ..Osteoclasts the cells responsible for bone resorption form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-:B (RANKL)...
  23. The Role Of Osteoclast PODXL, A Mediator Of Cell Adhesion, In Bone Metabolism
    Merry Jo Oursler; Fiscal Year: 2010
    ..Thus, loss of PODXL in early osteoclast lineage cells reduces bone resorption while preserving osteoblast recruitment and bone formation...
  24. COLONY STIMULATING FACTOR 1 REGULATION AND ROLE IN BONE
    Karl Insogna; Fiscal Year: 2002
    The precise mechanism whereby osteoblasts mediate osteoclastic bone resorption is unclear. One widely-held hypothesis is that activated osteoblasts secrete cytokines that directly or indirectly influence osteoclast formation or function...
  25. Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta
    Theresa Guise; Fiscal Year: 2005
    ..protein (PTHrP), originally identified as a hypercalcemic factor and a known stimulator of osteoclastic bone resorption, is a major mediator of the osteolytic process...
  26. CYTOKINE REGULATION OF RA SYNOVIOCYTE PHENOTYPE
    Lionel B Ivashkiv; Fiscal Year: 2010
    ..in RA pathogenesis by production of cytokines that drive inflammation, and osteoclasts mediate pathologic bone resorption. Osteoclast differentiation is dependent on the TNF family member RANKL...
  27. Amelioration of Immune Cell-Mediated Periodontal Disease
    Martin A Taubman; Fiscal Year: 2010
    ..demonstrated unequivocally that host immune responses play a key role in activating osteoclasts and promoting bone resorption in periodontal disease...
  28. Amelioration of Immune Cell-Mediated Periodontal Disease
    Martin Taubman; Fiscal Year: 2009
    ..demonstrated unequivocally that host immune responses play a key role in activating osteoclasts and promoting bone resorption in periodontal disease...